Supernus and Pacira swoop while their targets are down
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
US opioid crisis package nears enactment
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.